*AE = Adverse Event; a = the number of reports involving the drug of interest j and adverse event of interest i combination; b = reports of adverse event of interest i observed with other drugs; c = r
The aim of this study is to monitor, identify, and compare the adverse events (AEs) related to tenecteplase and alteplase, with the objective of exploring the potential safety of tenecteplase for acut
In France, the Levothyrox case is an extremely mediated pharmacovogilance case which received a lot of media coverage in August 2017 following the change, in March of the same year, of the pharmaceuti
